Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-924 Phase III Long-term Study in Hypercholesterolemia
jRCT2080225088Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of K-924 in hypercholesterolemia, familial hypercholesterolemia (FH), coronary arteriosclerosis and 2 more, sponsored by Kowa Company, Ltd. Primary endpoint: LDL-C percent change from baseline (Friedewald formula). Started Feb 2020; status: completed.
02
Drugs
K-924
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)coronary arteriosclerosisacute coronary syndrome (ACS)diabetes mellitus (DM)
Beyond the preview
Go deeper on jRCT2080225088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225088.